A new HIV drug combination could save SA billions of rands – plus it would be easier and safer for patients to take. Launched on Monday, the ADVANCE study will evaluate a HIV treatment regimen including two newer and cheaper drugs: dolutegravir (DTG) and tenofovir alafenamide (TAF). “If successful, patients will benefit from a much safer and more forgiving drug regimen in a smaller tablet,” said Francois Venter, Deputy Director of the Wits Reproductive Health and HIV Institute (WRHI)……more